Soluble Urokinase Plasminogen Activator Receptor: A Biomarker for Predicting Complications and Critical Care Admission of COVID-19 Patients

Chalkias, Athanasios; Mouzarou, Angeliki; Samara, Evangelia; Xanthos, Theodoros; Ischaki, Eleni; Pantazopoulos, Ioannis

doi:10.1007/s40291-020-00481-8

Cited by 24 publications

(24 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In daily clinical practice, suPAR is an easily measured inflammatory biomarker. Results can quickly be obtained on-site in many hospital settings, even in the emergency department, avoiding the need for samples to be passed through the clinical laboratory, or can even be obtained prior to hospitalization (time to result 20 min) guiding clinicians' decisions [10].…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Plasma Soluble Urokinase Plasminogen Activator Receptor Levels in Patients With COVID-19 and Non-COVID-19 Pneumonia: An Observational Cohort Study

et al. 2021

View full text Add to dashboard Cite

Background:The respiratory system is the main system affected by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and a great number of infected people need hospitalization. Soluble urokinase plasminogen activator receptor (suPAR) is a biomarker indicative of acute and chronic inflammation. Current literature supports that suPAR has great predictive ability for mortality in patients with coronavirus disease 2019 . The aim of this study was to compare the value of suPAR and other laboratory biomarkers in patients with chest infection and suspected COVID-19.Methods: A total of 41 consecutive patients with chest infection were enrolled in the study and were assigned into two groups according to the real-time polymerase chain reaction (PCR) result for SARS-CoV-2. The two groups had no significant difference in baseline data (age, sex), arterial oxygen partial pressure (PO 2 )/fraction of inspired oxygen (FiO 2 ) ratio and mortality.Results: Among patients with chest infection who required hospitalization, suPAR was significantly higher on admission in those with COVID-19 when compared to patients with non-COVID-19. suPAR had a great prognostic ability for in-hospital mortality in the COV-ID-19 subgroup. Conclusions:A single measurement of suPAR on admission can provide prognostic information for patients with suspected COVID-19 pneumonia. In the subgroup of patients with positive real-time PCR result for SARS-CoV2, suPAR was significantly higher and had an excellent prognostic value for the in-hospital mortality.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of Plasma Soluble Urokinase Plasminogen Activator Receptor Levels in Patients With COVID-19 and Non-COVID-19 Pneumonia: An Observational Cohort Study

et al. 2021

View full text Add to dashboard Cite

show abstract

“…A promising prognostic biomarker called soluble urokinase plasminogen activator receptor (suPAR) is currently used across various hospitals in Europe to manage COVID-19 patients. suPAR is a protein in the blood that reflects immune activation [ 52 ]. It has been demonstrated that the admission suPAR level is an early indicator for the risk of developing severe respiratory failure and requiring mechanical ventilation [ 53 ].…”

Section: Lab Tests Associated With Worse Prognosismentioning

confidence: 99%

“…Using admission suPAR levels for COVID-19 patients, physicians may identify low-risk patients for early discharge to reduce the pressure on COVID-19 emergency departments. Furthermore, physicians may identify high-risk patients for early treatment [ 52 ]. A recent study by Rovina et al evaluated whether the suPAR level at the time of admission could identify patients who would likely develop severe respiratory failure within the first 14 days [ 53 ].…”

Section: Lab Tests Associated With Worse Prognosismentioning

confidence: 99%

Management of COVID-19 Patients in the Emergency Department

Pantazopoulos

Tsikrika

Kolokytha

et al. 2021

JPM

Self Cite

View full text Add to dashboard Cite

COVID-19 is an emerging disease of global public health concern. As the pandemic overwhelmed emergency departments (EDs), a restructuring of emergency care delivery became necessary in many hospitals. Furthermore, with more than 2000 papers being published each week, keeping up with ever-changing information has proven to be difficult for emergency physicians. The aim of the present review is to provide emergency physician with a summary of the current literature regarding the management of COVID-19 patients in the emergency department.

show abstract

“…Azam et al [66] have found median suPAR value of 5.61 ng/ml and suPAR can be used to predict acute kidney injury in SARS-CoV-2 infection. Chalkias et al [67] have found elevated level of suPAR and concluded that suPAR can be utilized as triage biomarker for predicting admission in critical care and complication of SARS-CoV-2 infection. suPAR can be measured on automated platform by enzyme immunoassay, turbidimetric assay, and lateral flow immunoassay quick test which use two types of monoclonal antibodies [64].…”

Section: Utility Of Strem-1 In Sars-cov-2 Infectionmentioning

confidence: 99%

Utility of P-SEP, sTREM-1 and suPAR as Novel Sepsis Biomarkers in SARS-CoV-2 Infection

Dholariya

Parchwani

et al. 2021

Ind J Clin Biochem

View full text Add to dashboard Cite

The coronavirus disease 2019 is a highly contagious viral infection caused by SARS-CoV-2 virus, member of coronaviridae family. It causes life threatening complications due to complexity and rapid onset course of the disease. Early identification of high-risk patients who require close monitoring and aggressive treatment remains challengeable till date. Novel biomarkers which help to identify high risk patients at the early stage is high priority. Objective of this review to find utility of P-SEP, sTREM-1 and suPAR for diagnosis, risk stratification and prognosis of SARS-CoV-2 infected cases. Soluble receptors like, P-SEP, sTREM-1 and suPAR have been involved in immune regulation in SARS-CoV-2 infection and elevate more in severe cases. A comprehensive research of databases like PubMed, EMBASE, CNKI and Web of Science was performed for relevant studies. A total of nine out of fifteen research literature in initial screening were included for this review. Interestingly all studies have reported high levels of P-SEP, sTREM-1 and suPAR in SARS-CoV-2 infected cases and the biomarkers positively correlated with severity of infection. This implies that P-SEP, sTREM-1 and suPAR can be implemented as surrogate marker in blood profile for early diagnosis, risk stratification and prognosis in SARS-CoV-2 for better management in Indian population at the current situation.converting enzyme 2 Covid-2019 Coronavirus disease 2019 DIC Disseminated intravascular coagulation ORF Open reading frame SARS-CoV-2 Severe acute respiratory syndrome coronavirus-2 sTREM-1 Soluble triggering receptor expressed on myeloid cells suPAR Soluble Urokinase-type plasminogen activator receptor TMPRSS2 Transmembrane protease, serine 2

show abstract

Soluble Urokinase Plasminogen Activator Receptor: A Biomarker for Predicting Complications and Critical Care Admission of COVID-19 Patients

Cited by 24 publications

References 34 publications

Evaluation of Plasma Soluble Urokinase Plasminogen Activator Receptor Levels in Patients With COVID-19 and Non-COVID-19 Pneumonia: An Observational Cohort Study

Evaluation of Plasma Soluble Urokinase Plasminogen Activator Receptor Levels in Patients With COVID-19 and Non-COVID-19 Pneumonia: An Observational Cohort Study

Management of COVID-19 Patients in the Emergency Department

Utility of P-SEP, sTREM-1 and suPAR as Novel Sepsis Biomarkers in SARS-CoV-2 Infection

Contact Info

Product

Resources

About